Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, double-blind, vehicle-controlled Phase 2 study of INM-755 (cannabinol) cream in epidermolysis bullosa
2021-000214-42Phase 2Completed
- Sponsor
- InMed Pharmaceuticals Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epidermolysis bullosa (EB) comparing INM-755 (cannabinol) cream with Vehicle cream (2 arms). Primary endpoints: Primary safety endpoints and Systemic exposure to cannabinol. Started Apr 2021; status: completed.
02
Drugs
cannabinol
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2021-000214-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000214-42.